Pneumococcal vaccine, polyvalent

Pneumococcal Vaccine, Polyvalent (Pneumovax-23) Quadravalent Human Papillomavirus (Types 6, 11, 16, 18)... 

Pneumococcal Vaccine, Polyvalent (Pneumovox-23) [Vaccine/ Inactive Bacteria] Uses Immunization against pneumococcal Infxns in pts at high risk (eg, all = 65 y of age) Action Active immunization Dose 0.5 mL EM. Caution [C, ] Contra Do not vaccinate during immunosuppressive thCTapy Disp Inj SE Fever, inj site Rxn, hemolytic anemia, thromboc5rtopenia, anaphylaxis Interactions Effects W/ corticosteroids, immunosuppressants EMS None OD ... 

Vaccines Pneumococcal vaccine, polyvalent, 23 types of S. pneumoniae PNU-Immune- 23 0.5 ml dose contains 26 pg polysaccharide antigen purified from 23 serotypes of S. pneumoniae IM,SC NA NA NA Single 0.5 ml dose NA NA... 

Pneumococcal vaccine polyvalent [FDA] Pneumococcal vaccine, polyvalent [FDA former]... 

One dose of the polyvalent pneumococcal vaccine is indicated for patients at any age with COPD revaccination is recommended for patients older than 65 years if the first vaccination was more than 5 years earlier and the patient was younger than 65 years. 

Gabor EP, Seeman M. Acute febrile systemic reaction to polyvalent pneumococcal vaccine. JAMA 1979 242(20) 2208-9. 

Measel studied antibody response after manipulation twice daily for a week combined with administration of a polyvalent pneumococcal vaccine. The study subjects showed a significant increase in antibody response to many of the subserotypes when compared to matched control subjects. An unpublished study by this author found a trend toward increased white blood cell count in the majority of treated subjects as compared to controls within 1 hour after treatment. There was a significant increase in the lymphocyte absolute number and an insignificant decrease in hemoglobin as measured at an independent laboratory. 

Riley ID, Tarr PI, Andrews M, et al. Immunisation with a polyvalent pneumococcal vaccine. Lancet 1977 1 1338-1341. 

NMR can also be used to elucidate the structural features of a repeating unit in a polysaccharide and to investigate the conformation and dynamics of polysaccharides.21 A unique polysaccharide structure results in a characteristic proton NMR spectrum. Therefore, NMR is a powerful tool for identifying polysaccharide structures. This remarkable specificity has led to the development of a routine NMR-based identity assay, recently reported by Abeygunawardana et al. for quality control testing of bacterial polysaccharide to be used in formulating a polyvalent pneumococcal polysaccharide vaccine.22... 

Table 7 Mouse IgG and IgM Antibody Response (OD Unit of ELISA) of Four Types of Pneumococcal Polysaccharides Present in X-ray Irradiated Polyvalent Pneumococcal Polysaccharide Vaccine Lot A (Liquid) and of Corresponding Nonirradiation Controls of the Same Polysaccharide Type in Lot A... 

This vaccine is protective against invasive pneumococcal infections in immunocompetent adults [15]. Table 7 [14] lists the mouse IgG and IgM antibody response of four types of pneumococcal polysaccharide present in X-ray irradiated Polyvalent Pneumococcal Polysaccharide Vaccine Lot A and in a corresponding non-irradiated controls of the same polysaccharide type in Lot A. The type 9V, 14, 18C, and 19F polysaccharide samples were irradiated with X-rays at 24 kGy at room temperature and with X-rays at 13kGy at liquid nitrogen temperature. In each case for both the IgG and IgM mouse antibody responses there appeared to be no significant difference between the irradiated samples and the controls. 

JC May, L Rey, CJ Lee, J Arciniega. Evaluation of pneumococcal conjugate and polyvalent vaccines and other biological products irradiated by x-rays and gamma rays. Radiat Phys Chem. In press. 

ED Shapiro, AT Berg, R Austrian, D Schroeder, V Parcells, A Marglis, RK Adair, JD Clemens. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New Eng J Med 325 1453-1460, 1991. 

Boroono JM, McLean AA, Vella PP, et al. Vaccination and revaccination with polyvalent pneumococcal polysacchande vaccines in adults and infants. Proc Soc Exp BioL Med 1978 157 148-154. 

---